How I Use Aspirin to Unclog Arteries

Most people think aspirin is a simple call. Take 81mg a day. Protect your heart. Done.

That thinking is about 20 years out of date.

The decision is much more specific now — and the factor that matters most is one your doctor probably never checked: whether plaque is already living in your arteries. Aspirin decisions are routinely made based on age, cholesterol, and risk calculators — tools that don't actually look inside arteries. That's where the real risk lives. Here we'll explain how aspirin works, when it helps, when it doesn't, and what should actually be driving the call.

Does Aspirin Actually Prevent Heart Attacks?

It depends on whether you already have plaque. For people who have had a heart attack, stroke, or stent, aspirin clearly helps — clinical trials show about a 20% reduction in recurrent events. For people who haven't had an event yet, the benefit is less certain, and bleeding risk can outweigh it. The deciding factor isn't your age or your cholesterol number. It's whether plaque is already present in your arteries. If it is, you're managing established disease. If it isn't, aspirin has very little to protect you against — and meaningful risks that come with it.

Why the Aspirin Decision Matters More Than Most People Realize

Aspirin is one of the most widely used medications in the world. Millions of people take it daily for heart protection. Many were told to start years ago and have never had the decision revisited. That's a problem — because the evidence has shifted, guidelines have tightened, and the blanket recommendation to take aspirin before any cardiac event has occurred is no longer supported for most people.

That doesn't mean aspirin is ineffective. It means the decision needs to be more precise.

Platelet aggregation is the process by which blood cells clump together to form a clot — and aspirin works by blocking the specific enzyme that drives this process, making dangerous clots less likely to form at the site of a plaque rupture.

When that clot forms inside a coronary artery after plaque ruptures, it blocks blood flow and causes a heart attack. Aspirin reduces that risk — but only if there's plaque present and at risk of rupturing. Without plaque, there's less to protect against. And with the real bleeding risk aspirin carries, the math stops working in your favor.

The Biggest Mistake People Make About Aspirin

The common belief is that aspirin is a general heart-protection pill — something everyone should take as they get older, the way they'd take a multivitamin. In clinical practice, that belief causes real harm.

People take aspirin for decades without ever having their plaque status checked. Others stop taking it because they read a headline saying aspirin is risky — without understanding that the risk-benefit calculation depends entirely on whether arterial disease is already present.

The deeper problem is the framing. The question most doctors ask is: "Have you had a heart attack?" That's the wrong starting point. The right question is: "Do you already have plaque in your arteries?" Those two questions have very different answers in a lot of patients — and the aspirin decision follows from the second one, not the first.

What's Really Happening Inside the Body

Most people believe heart attacks happen when an artery slowly clogs until blood can't get through. That's not usually how it works.

The more common story: soft plaque builds silently in the artery wall over 20 to 30 years. That plaque develops a thin, fragile cap. When the cap ruptures — often triggered by inflammation, stress, or a spike in blood pressure — the body reads it as an injury. Platelets rush to the site. A clot forms fast. That clot blocks blood flow. Heart attack.

Plaque is the fuel. Clotting is the spark. Aspirin doesn't remove the fuel. It reduces the chance that the spark becomes a fire.

Geek Warning: The Deeper Science

Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, blocking the production of thromboxane A2 — a potent driver of platelet aggregation and vasoconstriction. Platelets have no nucleus and can't regenerate the enzyme, so the effect lasts the full lifetime of the platelet, roughly 7 to 10 days.

This mechanism is effective at the site of plaque rupture, where platelet-driven clotting is the primary event. It is far less effective — and mechanistically wrong — for clot types driven by coagulation factors rather than platelets. AFib-related clots, for example, require anticoagulants, not aspirin. The biology is completely different.

Not all plaque carries the same rupture risk. Stable plaque has a thick fibrous cap, lower inflammatory activity, and is often calcified — lower short-term risk despite potential size. Unstable, soft plaque has a thin cap, a large lipid core, and high inflammatory signaling — far more likely to rupture. The largest blockage is not always the most dangerous one. A 40% stenosis with vulnerable plaque can be more dangerous than a 70% stenosis with stable calcified plaque. This is why imaging that assesses plaque character matters, not just plaque size.

Signs You May Need a More Careful Evaluation

Not everyone needs a full imaging workup before making an aspirin decision. But some patterns suggest the standard approach is missing something:

• You've taken daily aspirin for years but have never had imaging to confirm plaque is present
• You were labeled "low risk" based on cholesterol and blood pressure alone, with no CAC scan or CIMT
• You have a family history of early heart disease — a parent or sibling with a heart attack before 60
• You have prediabetes, insulin resistance, or metabolic syndrome that risk calculators underweight
• You've had GI symptoms on aspirin but assumed that's just part of taking it

Research shows roughly 75% of men by age 60 have detectable calcified plaque. Women follow about 5 to 10 years later. "No event yet" is not the same as "no plaque yet."

Why Standard Testing May Not Be Enough

Standard cardiovascular risk tools estimate the probability that plaque might develop. They cannot tell you whether it already has. And that estimate can be significantly wrong in both directions.

A 55-year-old with borderline cholesterol and normal blood pressure might be classified as low risk while already carrying meaningful subclinical plaque. The gap between "risk calculator" and "actual plaque status" is where most aspirin decisions go wrong. Specifically:

• A stress test shows whether blood flow is obstructed — it doesn't reveal plaque burden or character
• Cholesterol levels don't show whether plaque exists or how stable it is
• CAC scores show calcified plaque but miss soft, non-calcified, vulnerable plaque
• CIMT measures arterial wall thickness directly — a more complete picture of vascular aging
• Symptoms are a late signal — most first cardiac events occur in people who felt fine

The tools that actually inform the aspirin decision are rarely the ones leading the conversation.

How We Think About Aspirin at PrevMed

At PrevMed Health, we don't start the aspirin conversation with age or cholesterol. We start with a better question: is there evidence of plaque, and what does that plaque look like? That means looking at the full picture before making a recommendation:

• CAC score — quantifies calcified plaque; a score above zero changes the conversation
• CIMT — direct measure of arterial wall thickness and vascular aging
• CTA with AI plaque analysis — where appropriate, gives the most complete picture of both calcified and soft plaque
• Inflammatory markers — hsCRP, Lp-PLA2, MPO; high inflammation alongside plaque elevates rupture risk
• Metabolic markers — fasting insulin, triglyceride-to-HDL ratio, OGTT; these drive plaque progression

Then the aspirin decision fits into that picture:

For most patients without a prior event, we also address root causes directly — because aspirin doesn't fix what's building the plaque. Improving metabolic health, reducing systemic inflammation, controlling blood pressure, and addressing insulin resistance change the trajectory of the disease. Aspirin manages one downstream risk. It doesn't change the upstream biology.

What You Should Actually Do

1. Find out if you have plaque. If you're 45 or older with any risk factors — family history, metabolic issues, elevated blood pressure — ask about a CAC scan. It's the most practical starting point.
2. Know your bleeding risk. GI bleeding history, current anticoagulant use, or prior hemorrhagic stroke changes the math. Be explicit with your doctor about these before starting aspirin.
3. Clarify whether you're in primary or secondary prevention. Prior cardiac event — aspirin is almost certainly appropriate. No prior event — the decision depends on what's actually in your arteries, not what a risk calculator estimates.
4. Use the right dose. 81mg is standard for cardiovascular prevention in the U.S. Higher doses increase bleeding risk without adding cardiovascular benefit. More is not better.
5. Address the underlying drivers. Aspirin is one tool. Metabolic health, inflammation control, sleep, and insulin resistance are the real levers for long-term disease management.

When You Should Talk to a Clinician

This decision should not be made based on a news headline. Seek a direct conversation if any of the following apply:

• You've taken daily aspirin for years but haven't had your plaque status checked
• You stopped aspirin after a news story but have a history of plaque or a prior cardiac event
• You're having GI symptoms on aspirin and haven't discussed stopping or switching
• You have a strong family history of early heart disease and have never been fully evaluated
• You're on both aspirin and an anticoagulant — that combination needs close clinical oversight

Frequently Asked Questions

Does aspirin remove plaque from arteries?

No. Aspirin does not remove plaque, dissolve blockages, or reverse arterial disease. What it does is reduce platelet aggregation — making it less likely that a plaque rupture triggers the rapid clot formation that causes a heart attack. The plaque itself requires lifestyle change, metabolic management, and in some cases medications to address.

What is the difference between primary and secondary prevention for aspirin?

Secondary prevention means you've already had a heart attack, stroke, or cardiac procedure — aspirin is used to prevent another event. Primary prevention means you haven't had an event yet. The evidence for aspirin is clear in secondary prevention. In primary prevention, the key variable is whether plaque is already present, not age or cholesterol alone.

Is 81mg aspirin better than a full-dose tablet for heart protection?

For cardiovascular prevention, 81mg is the dose we use when aspirin is appropriate. Higher doses do not improve outcomes and significantly increase GI bleeding risk and other side effects. The cardiovascular benefit plateaus at low dose — more aspirin does not mean more protection.

What if I can't tolerate aspirin?

Clopidogrel works through a different mechanism and is a valid alternative for many patients who can't tolerate aspirin. In high-risk situations — such as after a coronary stent — dual antiplatelet therapy combining both may be appropriate. That's a physician-guided decision based on the specific clinical picture.

Should aspirin be taken at night or in the morning?

There is some data suggesting evening dosing may better counteract the morning surge in platelet activity, when heart attacks occur most frequently. The evidence is not definitive. Consistency matters more than timing — take it at whatever time you'll reliably remember every day.

What other risks does aspirin carry?

The primary concern is bleeding — particularly GI bleeding, which can range from minor irritation to serious hemorrhage. Aspirin also slightly increases the risk of hemorrhagic stroke, even while reducing clot-based stroke risk. This is why the decision isn't one-size-fits-all, and why bleeding risk is always part of the calculation alongside cardiovascular benefit.

The Bottom Line

The aspirin decision should start with one question: is plaque already present? If it is, the conversation changes — because you're managing established disease, not preventing a theoretical future one. Aspirin doesn't remove plaque and doesn't fix the metabolic drivers behind it. What it does — when used correctly — is reduce the likelihood that a plaque rupture turns into a fatal clot. That's a meaningful tool, but only when it's the right tool for what's actually in your arteries.

If you'd like a practical starting point for understanding your full cardiovascular risk picture, the two options below are a good next step.

References

Fuster V, et al. JACC, 2005 · Libby P. NEJM, 2013 · Virmani R, et al. ATVB, 2000 · Patrono C, et al. Chest, 2004 · Antithrombotic Trialists' Collaboration, BMJ, 2002 · AHA/ACC Guidelines, Circulation, 2014 · USPSTF, JAMA, 2022 · Greenland P, et al. JACC, 2010 · Budoff MJ, et al. JACC, 2018 · Bhatt DL, Lancet, 2010 · Muller JE, Circulation, 1989 · Lanas A, Gut, 2006 · He J, JAMA, 1998 · Bhatt DL, NEJM, 2006 · Garg R, AJM, 2020

Additional reading

• Dr. Brewer’s story — how plaque at 57 led to PrevMed’s prevention-first practice.
• Frequently asked questions — what PrevMed does, how programs work, who’s a fit.

This article is for educational purposes and isn’t medical advice. Talk to a clinician about decisions specific to your health.